Why U.S. Biotech Companies Are Looking at China Now
China offers a compelling combination of clinical execution speed, hospital research capacity, CRO depth, and policy support. For many U.S. biotech companies, the opportunity is not just market entry. It is the ability to use China as a platform for faster evidence generation, IIT collaboration, translational work, and regional expansion.
Faster Clinical Execution
China offers distinct efficiency advantages in clinical startup and study execution. National mechanisms now mandate clear CTA timelines, while hubs like Shanghai are actively accelerating ethics reviews and site initiations.
IIT and Hospital Collaboration
Beyond setting up an entity, the core draw is the ability to partner with top Chinese hospitals and investigators to drive IITs, explore indications, and generate robust human evidence rapidly.
CRO and Incentive Advantage
Tap into a mature, cost-effective CRO ecosystem. Concurrently, hubs like Shanghai and Chengdu offer strong policy support, grants, and financial incentives for foreign R&D, biotech innovation, and clinical programs.
What We Do
We help U.S. biotech companies build a workable China operating path that connects entity setup, clinical execution, local partnerships, incentives, and compliance into one coordinated plan.
China Setup & Park Landing
We help clients establish the right China entity, select the right city or park, and build a workable local operating structure aligned with program goals.
IIT, Hospital, and CRO Execution
We support local collaboration pathways, hospital engagement, and CRO selection so programs can move faster with stronger execution control.
Incentives & Compliance
We help clients evaluate policy support, manage data and HGR risks, and design the right cross-border compliance path from day one. China's HGR and data transfer rules directly impact clinical design.
Choose the Right China Landing Model
The right city depends on your program goals, operating model, budget, and expansion plan. For many U.S. biotech companies, Shanghai and Chengdu represent two strong but different pathways.
Shanghai
Best for: Internationally oriented biopharma programs that need top-tier hospitals, foreign R&D center positioning, stronger policy coordination, and broader ecosystem visibility. Shanghai offers systematic support for foreign R&D and biomedical innovation.
Best for International Visibility
Chengdu
Best for: Execution efficiency, IIT-oriented collaboration, western China expansion, and cost-conscious operations. Chengdu and its Hi-Tech Zone offer highly execution-driven support for innovative drugs and clinical collaborations.
Best for Execution Efficiency
How We Work
Assess the Program
We review your stage, evidence goals, and China fit.
Build the China Path
We design the entity, location, partner network, and local operating structure.
Launch with Compliance
We support execution, incentive planning, and cross-border compliance.
China Opportunity Is Real.
Compliance Needs to Be Designed Early.
For U.S. biotech companies, the opportunity in China is meaningful, but the compliance architecture cannot be an afterthought. The right entry strategy should account for entity structure, patient data, human genetic resources, intercompany arrangements, and cross-border operating flows before the program begins to scale.
Human genetic resources (HGR) rules may apply when a program involves genomic or genetic information.
Patient data transfer should be assessed before information flows back to U.S. headquarters.
Entity structure, tax, and intercompany arrangements should be planned early, not after execution starts.
Start with a Practical China Entry Checklist
Get a concise checklist built for U.S. biotech teams evaluating China entry, IIT collaboration, clinical execution, local setup, and compliance planning.
Planning a China Entry Strategy for Your Program?
Whether you are exploring IIT collaboration, evaluating a China entity, comparing Shanghai and Chengdu, or looking for a more efficient CRO model, we can help you build a workable plan.
